On November 5, 2020 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that its CD40 targeting antibody mitazalimab will be presented at the World Immunotherapy Congress, November 2-6, 2020 (Press release, Alligator Bioscience, NOV 5, 2020, View Source [SID1234569885]). The presentation will include new benchmark data demonstrating that mitazalimab has the potential to be best-in-class in the CD40 field.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new preclinical data include analyses of mitazalimab compared with analogues of the CD40 antibodies of key competitors. The comparison demonstrates the potent immune-activating properties and anti-tumor effects of mitazalimab.

Mitazalimab’s mode of action is clearly dependent on Fc-gamma-receptor engagement, resulting in a more tumor-selective immune-activation. This differentiation may translate into a superior risk-benefit profile in patients.

The presentation will also summarize previously released clinical data from the Phase I study performed by Janssen Biotech Inc. Mitazalimab shows a manageable safety profile both with and without corticosteroid premedication. A partial response was observed in one patient with renal cell cancer and 10 patients with different advanced cancers showed stable disease lasting ≥ 6 months. In addition, clinical biomarker data confirm proof of mechanism in patients.

"The solid clinical package from Phase I and the new favorable benchmark data to our key competitors further strengthen our belief in mitazalimab as a potent immunotherapy agent. Mitazalimab has demonstrated strong activity and superior tolerability, which probably reflects the fact that the antibody has been optimized for more tumor-selective effects", said Per Norlén, CEO at Alligator Bioscience. "We are now completing the clinical file for the submission of the CTA for the upcoming Phase Ib/II efficacy study in pancreatic cancer," he added.

Dr Peter Ellmark, VP Discovery, Alligator Bioscience will give an oral presentation with the title "Mitazalimab – a CD40 agonist to unleash CD40 in immuno-oncology" on November 5, 2020, at 12:50 p.m CET. For further information, please see View Source

On November 5, 2020 Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that its Executive Vice President and Chief Scientific Officer, Eric Quéméneur, Pharm.D., PhD, will present today at the virtual 5th Annual Neoantigen Based Therapies Summit (Press release, Transgene, NOV 5, 2020, View Source [SID1234569884]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation

Title: Viral Immunotherapy Meets AI Technology
Session: Clinical Translation – Utilizing Different Delivery Platforms to Enhance Clinical
Timing: November 5th at 11.45 am ET / 5.45 pm CET
Éric Quéméneur, Pharm.D., Ph.D., Executive VP and Chief Scientific Officer of Transgene, said: "Viral immunotherapy constitutes a very promising modality based on harnessing the natural capabilities of the immune system to target cancer cells. TG4050 is an individualized cancer vaccine based on our myvac technology that has the ability to elicit an immune response against up to 30 patient-specific tumor neoantigens. Our partnership with NEC enables us to benefit from its cutting-edge AI capabilities that allows us to select the best combination of neoantigens to include in TG4050 to induce a strong anti-tumor immune response. We are convinced that the success of TG4050, which is at the crossroad of immunotherapy and big data sciences, will herald the start of a new era in the fight against cancer."

The Neoantigen Based Therapies Summit is the leading end-to-end meeting dedicated to delivering the promise of accurate identification, prediction, and validation of neoantigens to develop highly efficacious vaccines and cell therapies.

About TG4050
TG4050 is an individualized cancer vaccine based on the myvac platform; it is based on an optimized viral platform for cancer vaccination and integrates NEC’s artificial intelligence capabilities. This therapeutic vaccine aims at stimulating the immune system of patients to induce a T-cell response against tumor-specific antigenic alterations, called neoantigens. These neoantigens are derived from genomic mutations and selected using NEC’s Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. TG4050 has been designed to target up to 30 patient-specific neoantigens. Transgene is sponsoring two Phase 1 trials that are expected to deliver a first proof of concept of this virus-based individualized approach.

On November 4, 2021 PCI Biotech’s (OSE: PCIB) reported that third quarter 2020 interim report will be released on 11 November 2020 at 07.00 CET (Press release, PCI Biotech, NOV 4, 2020, View Source [SID1234585152]). The interim report and presentation will be made available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A results presentation (in English) will be held through a webcast at 08.30 CET the same day. The webcast can be accessed through www.pcibiotech.com and it will be possible to post questions through the webcast console.

On November 4, 2020 Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) reported the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion (Press release, Bristol-Myers Squibb, NOV 4, 2020, View Source [SID1234573352]). The expiration of the waiting period occurred at 11:59 p.m. EST on November 3, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction, which remains subject to the tender of a majority of the outstanding shares of MyoKardia’s common stock, as well as other customary closing conditions. Unless the tender offer is extended, the offer and withdrawal rights will expire at midnight (New York City time), one minute after 11:59 p.m. New York City time, on November 16, 2020.

On November 4, 2020 PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, reported that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 1:20 p.m. ET (Press release, PerkinElmer, NOV 4, 2020, View Source [SID1234570415]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jamey Mock, SVP and chief financial officer of PerkinElmer, will provide an update on the Company and its strategic priorities.

A live audio webcast of the presentation will also be available on the Investors section of the Company’s website at www.perkinelmer.com. A replay of the presentation will be posted on the PerkinElmer website after the event and will be available for 90 days following.